题目内容
On Jan 23, 2009, the first Phase I clinical trials for transplantation of oligodendrocytes derived from human embryonic stem cells (ESCs) into spinal cord-injured individuals received approval from the US FDA, which is conducted by Asterias Biotherapeutics now.
查看答案
搜索结果不匹配？点我反馈
更多问题
Becauseoftheircombinedabilitiesofunlimitedexpansion&pluripotency,embryonicstemcells (ESCs) remainatheoreticallypotentialsourceforregenerativemedicineandtissuereplacementafterinjuryordisease.
Human embryonic stem cells (ESCs) are now being tested in clinical trials as treatments for diabetes, spinal cord injury, heart failure, macular degeneration and Stargardt's macular dystrophy.
Embryoniccelllinesandautologousembryonicstemcells(ESCs)generatedthroughsomaticcellnucleartransferordedifferentiationhavebeenproposedaspromisingcandidatesforfuturetherapies.
For diabetes, heart diseases, stroke, etc. human embryonic stem cells (ESCs) provide an alternative source of tissue/organs which serves as a possible solution to the donor shortage dilemma.
微信支付 
支付宝支付